Canakinumab Tapering in Still's DiseaseAugust 20, 2020You can reduce – but not stop – canakinumab therapy in patients who are…View Resource
Canakinumab First FDA-Approved Therapy for Adult-Onset Still's DiseaseJune 17, 2020Yesterday, the FDA approved canakinumab (Ilaris) as treatment for adult-onset Still’s disease (AOSD), the…View Resource
TNR Grand Rounds – Cytokine Storm SyndromesMay 27, 2020This week’s Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama –…View Resource
High Dose Anakinra Effective in COVID-19May 18, 2020Anakinra was studied in 29 COVID(+) patients with respiratory distress and high inflammatory markers…View Resource
Earlier Anakinra Initiation Warranted in Still's DiseaseMarch 12, 2020An Italian study examined the outcomes in adult onset Still’s disease (AOSD) based on…View Resource
Canakinumab Use in Periodic Febrile DisordersJanuary 1, 1970A retrospective records review of patients with periodic fever syndromes (PFS) receiving IL-1 inhibitor…View Resource
Anakinra's Effects on COVID-19 OutcomesJanuary 1, 1970Sporadic reports of anakinra use in COVID-19 infection has hinted is potential; now a metanalysis…View Resource
Rhapsody Study: IL-1 Inhibition in Recurrent PericarditisJanuary 1, 1970Recurrent pericarditis is a rare, probable autoinflammatory disorder mediated by interleukin-1 (IL-1); and is often…View Resource